CAR-T Cell Therapy Market Size Trends Growth US$ 20.4 Billion by 2025-2033 | Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company,

CAR-T Therapies Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/car-t-cell-therapy-market?an

The Global CAR-T cell Therapy Market reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

CAR-T Therapies (PDT) is a medical treatment that uses a combination of light-sensitive drugs (photosensitizers) and a specific wavelength of light to destroy abnormal or cancerous cells. When exposed to light, the drug produces reactive oxygen species that damage targeted tissues. PDT is commonly used for treating certain cancers, skin conditions, and eye diseases, offering a minimally invasive and precise therapeutic approach.

List of the Key Players in the CAR-T Therapies Market:

Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson, Autolus Therapeutics, Pfizer Inc., BioNTech SE., Merck KGaA, Allogene Therapeutics, Atara Biotherapeutics, Inc. and among others.

Emerging Players

The emerging players in the CAR-T cell therapy market include AstraZeneca, Eli Lilly and Company, JW Therapeutics,

Industry Development:

In October 2024, Aurigene Oncology Limited announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study, marking India's first clinical trial for a novel autologous BCMA-directed CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

The growing number of FDA approvals for CAR-T therapy in multiple myeloma underscores its increasing significance in cancer treatment, expanding patient access as more CAR-T options become available. In April 2024, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (cilta-cel; Carvykti) and idecabtagene vicleucel (ide-cel; Abecma) for earlier-stage treatment of adults with multiple myeloma. Previously, patients were required to undergo at least four lines of therapy before qualifying for CAR-T treatment.

Growth Forecast Projected:

The Global CAR-T Therapies Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global CAR-T Therapies Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/car-t-cell-therapy-market

Segment Covered in the CAR-T Therapies Market:

By Therapy Type: Autologous CAR-T Cell Therapy , Allogeneic CAR-T Cell Therapy

By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta

By Target Antigen: CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others

By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, Others

Regional Analysis for CAR-T Therapies Market:

The regional analysis of the CAR-T Therapies Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/car-t-cell-therapy-market

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the CAR-T Therapies market?

➠ Who are the leading manufacturers in the global CAR-T Therapies industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global CAR-T Therapies industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the CAR-T Therapies market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.